🚀 VC round data is live in beta, check it out!
Dr. Lal PathLabs Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dr. Lal PathLabs and similar public comparables like BGI Genomics, Veracyte, HeartFlow, Tecan Group and more.
Dr. Lal PathLabs Overview
About Dr. Lal PathLabs
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
Founded
1995
HQ
Employees
5.0K
Website
Financials (LTM)
EV
$2B
Dr. Lal PathLabs Financials
Dr. Lal PathLabs reported last 12-month revenue of $296M and EBITDA of $84M.
In the same LTM period, Dr. Lal PathLabs generated $239M in gross profit, $84M in EBITDA, and $56M in net income.
Revenue (LTM)
Dr. Lal PathLabs P&L
In the most recent fiscal year, Dr. Lal PathLabs reported revenue of $288M and EBITDA of $85M.
Dr. Lal PathLabs expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $296M | XXX | $288M | XXX | XXX | XXX |
| Gross Profit | $239M | XXX | $177M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $84M | XXX | $85M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $56M | XXX | $55M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dr. Lal PathLabs Stock Performance
Dr. Lal PathLabs has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Dr. Lal PathLabs' stock price is $15.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.5% | XXX | XXX | XXX | $0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDr. Lal PathLabs Valuation Multiples
Dr. Lal PathLabs trades at 8.1x EV/Revenue multiple, and 28.6x EV/EBITDA.
EV / Revenue (LTM)
Dr. Lal PathLabs Financial Valuation Multiples
As of April 19, 2026, Dr. Lal PathLabs has market cap of $3B and EV of $2B.
Equity research analysts estimate Dr. Lal PathLabs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dr. Lal PathLabs has a P/E ratio of 45.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | 28.6x | XXX | 28.2x | XXX | XXX | XXX |
| EV/EBIT | 35.2x | XXX | 36.1x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | 13.6x | XXX | XXX | XXX |
| P/E | 45.3x | XXX | 45.7x | XXX | XXX | XXX |
| EV/FCF | 47.2x | XXX | 43.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dr. Lal PathLabs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dr. Lal PathLabs Margins & Growth Rates
Dr. Lal PathLabs' revenue in the last 12 month grew by 12%.
Dr. Lal PathLabs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Dr. Lal PathLabs' rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dr. Lal PathLabs' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dr. Lal PathLabs Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dr. Lal PathLabs Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dr. Lal PathLabs | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Veracyte | XXX | XXX | XXX | XXX | XXX | XXX |
| HeartFlow | XXX | XXX | XXX | XXX | XXX | XXX |
| Tecan Group | XXX | XXX | XXX | XXX | XXX | XXX |
| GRAIL | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Lal PathLabs M&A Activity
Dr. Lal PathLabs acquired XXX companies to date.
Last acquisition by Dr. Lal PathLabs was on XXXXXXXX, XXXXX. Dr. Lal PathLabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dr. Lal PathLabs
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDr. Lal PathLabs Investment Activity
Dr. Lal PathLabs invested in XXX companies to date.
Dr. Lal PathLabs made its latest investment on XXXXXXXX, XXXXX. Dr. Lal PathLabs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dr. Lal PathLabs
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dr. Lal PathLabs
| When was Dr. Lal PathLabs founded? | Dr. Lal PathLabs was founded in 1995. |
| Where is Dr. Lal PathLabs headquartered? | Dr. Lal PathLabs is headquartered in India. |
| How many employees does Dr. Lal PathLabs have? | As of today, Dr. Lal PathLabs has over 5K employees. |
| Is Dr. Lal PathLabs publicly listed? | Yes, Dr. Lal PathLabs is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Dr. Lal PathLabs? | Dr. Lal PathLabs trades under LALPATHLAB ticker. |
| When did Dr. Lal PathLabs go public? | Dr. Lal PathLabs went public in 2015. |
| Who are competitors of Dr. Lal PathLabs? | Dr. Lal PathLabs main competitors are BGI Genomics, Veracyte, HeartFlow, Tecan Group. |
| What is the current market cap of Dr. Lal PathLabs? | Dr. Lal PathLabs' current market cap is $3B. |
| What is the current revenue of Dr. Lal PathLabs? | Dr. Lal PathLabs' last 12 months revenue is $296M. |
| What is the current revenue growth of Dr. Lal PathLabs? | Dr. Lal PathLabs revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Dr. Lal PathLabs? | Current revenue multiple of Dr. Lal PathLabs is 8.1x. |
| Is Dr. Lal PathLabs profitable? | Yes, Dr. Lal PathLabs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dr. Lal PathLabs? | Dr. Lal PathLabs' last 12 months EBITDA is $84M. |
| What is Dr. Lal PathLabs' EBITDA margin? | Dr. Lal PathLabs' last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Dr. Lal PathLabs? | Current EBITDA multiple of Dr. Lal PathLabs is 28.6x. |
| What is the current FCF of Dr. Lal PathLabs? | Dr. Lal PathLabs' last 12 months FCF is $51M. |
| What is Dr. Lal PathLabs' FCF margin? | Dr. Lal PathLabs' last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Dr. Lal PathLabs? | Current FCF multiple of Dr. Lal PathLabs is 47.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.